| 32.3738 0.944 (3%) | 09-25 14:53 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 40.72 | 1-year : | 43.99 |
| Resists | First : | 34.87 | Second : | 37.66 |
| Pivot price | 32.98  |
|||
| Supports | First : | 30.35 | Second : | 25.25 |
| MAs | MA(5) : | 31.94 |
MA(20) : | 33.43 |
| MA(100) : | 36.02 |
MA(250) : | 34.07 |
|
| MACD | MACD : | -1.4 |
Signal : | -1.4 |
| %K %D | K(14,3) : | 22 |
D(3) : | 19.7 |
| RSI | RSI(14): 39.5 |
|||
| 52-week | High : | 43.72 | Low : | 13.72 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ COGT ] has closed above bottom band by 34.5%. Bollinger Bands are 15.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 31.97 - 32.12 | 32.12 - 32.27 |
| Low: | 29.97 - 30.14 | 30.14 - 30.3 |
| Close: | 31.15 - 31.42 | 31.42 - 31.67 |
Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib. Previously known as Unum Therapeutics Inc., the company adopted its current name, Cogent Biosciences, Inc., in October 2020. Established in 2014, Cogent Biosciences is headquartered in Cambridge, Massachusetts.
Fri, 25 Sep 2026
Cogent Biosciences, Inc. (COGT) Stock Price, News, Quote & History - ca.finance.yahoo.com
Thu, 24 Sep 2026
Cogent Biosciences (COGT) Looks Fully Valued Following FDA NDA Acceptance - Yahoo Finance
Thu, 24 Sep 2026
Will FDA’s Streamlined Bezuclastinib Review in ASM Change Cogent Biosciences’ (COGT) Narrative? - Yahoo Finance
Mon, 21 Sep 2026
Cogent Biosciences (COGT) Stock Price, News & Analysis - Stock Titan
Fri, 18 Sep 2026
Cogent Biosciences, Inc. (COGT) Stock Analysis: Unveiling A Potential 68% Upside - DirectorsTalk Interviews
Thu, 17 Sep 2026
Here’s How Much You Would Have Made Owning Cogent Biosciences Stock In The Last 5 Years - Benzinga
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 174 (M) |
| Shares Float | 173 (M) |
| Held by Insiders | 0.4 (%) |
| Held by Institutions | 114.9 (%) |
| Shares Short | 18,410 (K) |
| Shares Short P.Month | 16,560 (K) |
| EPS | -2.17 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.72 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -43.9 % |
| Return on Equity (ttm) | -109.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.23 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -308 (M) |
| Levered Free Cash Flow | -186 (M) |
| PE Ratio | -14.94 |
| PEG Ratio | 0 |
| Price to Book value | 11.86 |
| Price to Sales | 0 |
| Price to Cash Flow | -18.21 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|